Cellectis (CLLS) Tops Q3 EPS by 26c

Cellectis (NASDAQ: CLLS) reported Q3 EPS of ($0.54), $0.26 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $2.19 million versus the consensus estimate of $3.28 million.

“The third quarter of 2019 has been essential for our execution strategy, as we achieved a series of important key milestones that enable us to move our proprietary allogeneic UCART product candidates into Phase 1 clinical trials,” said Dr. André Choulika, Chairman and CEO, Cellectis. “We are pleased to announce the first patient dosing in our MELANI-01 clinical trial for UCARTCS1, our UCART product candidate in relapsed/refractory multiple myeloma. We are also building out our clinical leadership team with the core addition of oncology veteran Dr. Francisco Esteva, M.D., Ph.D., as VP, Clinical Development. Following Novartis’ acquisition of CellforCure, our first CMO partner, at the beginning of 2019, we strengthened our manufacturing capabilities with the addition of our new CMO partner, Lonza, in addition to our existing partner MolMed S.p.A., while we remain on track with the construction of our in-house manufacturing facilities SMART and IMPACT. With three partnered and three stand-alone clinical development programs ongoing in hematology, Cellectis continues to be best-positioned to find new cures for cancers leveraging its core proprietary technologies.”

For earnings history and earnings-related data on Cellectis (CLLS) click here.

You May Also Be Interested In

• Boot Barn Holdings (BOOT) Tops Q4 EPS by 5c; offers weaker guidance
• Sonim Technologies (SONM) Misses Q1 EPS by 8c
• Investcorp Credit Management BDC, Inc. (ICMB) Tops Q1 EPS by 1c